Page 5 - Samsung Biologics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Seoul shares soar over 2% on looming hopes for US rate cuts

South Korean shares shot up over 2 percent Tuesday as investors were buoyed by growing hopes that the U.S. Federal Reserve may carry out rate cuts this year. The local currency gained against the U.S. dollar. The benchmark Korea Composite Stock Price Index jumped 57.73 points, or 2.16 percent, to close at 2,734.36. Trading volume was moderate at 523 million shares worth 10.9 trillion won ($8 billion), with winners ou.

United statesSouth koreaSouth koreanSamsung biologicsHan ji youngSamsung electronicsLg energy solutionKorea composite stock price indexWall streetHyundai motorsHyundai mobisSamsung life insuranceThe korea heraldOrean newsOuth korea newsOuth korea news in english

Samsung Biologics poised for growth pending BIOSECURE bill approval in US

Samsung Biologics poised for growth pending BIOSECURE bill approval in US
biopharma-reporter.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biopharma-reporter.com Daily Mail and Mail on Sunday newspapers.

Inch on gwangyoksiSouth koreaNew jerseyUnited statesSouth koreanSamsung biologicsJithendra kancharlaBristol myers squibbFujifilm corpWuxi apptecSwedish headquartered recipharmBiosecure act

Goldman added these global stocks to its conviction list

CNBC Pro looks at three additions to Goldman's "directors' cut" of top global stocks that were given more than 30% upside potential.

United kingdomSouth koreaSouth koreanZiyi chenSamsung biologicsOliver carruthersSamsung biologics goldmanSamsung bioGoldman sachsBritain london stock exchangeInvestment review committeeLondon stock exchange goldmanEu renewable energy directiveStock exchange goldmanLondon stock exchangeBiologics goldman

Samsung Life Science Fund invests in US gene therapy firm

Samsung Life Science Fund, an investment fund created by Samsung affiliates, will invest in Latus Bio, a US gene therapy development company, according to Samsung Bioepis on Friday. It is the sixth investment made by the fund between Samsung Biologics, Samsung C&T and Samsung Bioepis, to explore new business opportunities in the biotechnology sector. The exact amount of investment has not been disclosed. Latus Bi.

United statesSamsung biologicsLatus bioSamsung bioepisAmerican society of gene cell therapyChildren hospital of philadelphia foundationSamsung life science fundDevelopment of samsung bioepisHead of early researchBenjamin franklin technology partnersCho ho sungExecutive vice presidentEarly researchPhiladelphia foundationModi venturesAmerican society

Latus Bio Raises $54M in Series A Financing

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

United statesCeop peter ghoroghchianLatus bioBeverly davidsonSamsung biologicsSamsung bioepisBenjamin franklin technology partnersChildren hospital of philadelphia foundationSamsung venture investment corporationSamsung life science fundPhiladelphia foundationModi venturesJang ho cha